Table 4. Distribution of patients with increased systolic and diastolic blood pressureabove the recommendations (SBP>140 mmHg and DBP>90 mmHg) at baseline and the 2nd followup visit. A-lisinopril and/or lisinopril +hydrochlorothiazide; B-losartan and/or losartan + hydrochlorothiazide; C-valsartan and/or valsartan +hydrochlorothiazide; D-lisinopril and/or lisinopril+hydrochlorothiazide and amlodipine; E-losartan and/or losartan + hydrochlorothiazide and amlodipine; F-valsartan and/or valsartan +hydrochlorothiazide and amlodipine.
| A N=237 |
B N=78 |
C N=180 |
D N=81 |
E N=29 |
F N=60 |
p | ||
|---|---|---|---|---|---|---|---|---|
| SBP>140 mmHg | Baseline | 57.0% | 67.9% | 75.0% | 71.6% | 69.0% | 90.0% | 0.001 |
| 2nd follow-up | 23.9% | 16.0% | 33.1% | 29.6% | 31.0% | 21.1% | 0.07 | |
| DBP>90 mmHg | Baseline | 47.2% | 55.1% | 53.3% | 59.3% | 69.3% | 68.3% | 0.025 |
| 2nd follow-up | 23.0% | 14.7% | 24.5% | 23.5% | 13.8% | 24.6% | 0.48 |